| Place of Origin: | China |
|---|---|
| Brand Name: | BOSI |
| Model Number: | 123-39-7 |
| Minimum Order Quantity: | Negotiable |
| Price: | Negotiable |
| Packaging Details: | 200 kg/drum |
| Payment Terms: | T/T |
| Supply Ability: | 50000 L / month |
| Alias: | N-MENTHYL FORMAMID | Purity: | 99% |
|---|---|---|---|
| CAS NO.: | 123-39-7 | Type: | Chemical Intermediate |
| Viscosity: | 1.261 MPa·s At 45ºC | Flash Point: | 111 ℃ |
| High Light: | NMF Organic Raw Materials,rganic Raw Materials NO 123-39-7,CAS NO 123-39-7 Colorless Liquid |
||
NMF Organic Raw Materials CAS NO 123-39-7 colorless Liquid
The antitumour activities of N-methylformamide, N-ethylformamide and formamide against a number of murine tumours in vivo (Sarcoma 180, M5076 ovarian sarcoma and TLX5 lymphoma) have been estimated. In all cases N-methyl-formamide had significant activity, formamide had marginal or no activity and N-ethylformamide had no significant activity. N-methylformamide and N-ethylformamide were equitoxic to the TLX5 lymphoma in vitro. Formamide was found as a metabolite in the plasma and urine of animals given N-methylformamide and N-ethylformamide, but excretion profiles do not support the hypothesis that formamide is an active antitumour species formed from N-alkylformamides. No appreciable metabolism of N-methylformamide occurred under a variety of conditions with liver preparations in vitro. N-methylformamide, but not N-ethylformamide or formamide, reduced liver soluble non-protein thiols by 59.8% 1 h after administration of an effective antitumour dose.
| ITEM | CONTENT |
| Purity | 99% |
| Characters | Solvents and intermediates for organic synthesis |
| Viscosity | 1.261 mPa·s at 45ºC |
| Other Name | Methylformamide |
| CAS No. | 123-39-7 |
| Type | Organic chemical industry |
| EINECS No. | 204-624-6 |
| Flash Point | 111 ℃ |
| Density | 0.873g/cm³ |
| Toxicity grading | Intoxication |
The antitumour activities of N-methylformamide, N-ethylformamide and formamide against a number of murine tumours in vivo (Sarcoma 180, M5076 ovarian sarcoma and TLX5 lymphoma) have been estimated. In all cases N-methyl-formamide had significant activity, formamide had marginal or no activity and N-ethylformamide had no significant activity. N-methylformamide and N-ethylformamide were equitoxic to the TLX5 lymphoma in vitro. Formamide was found as a metabolite in the plasma and urine of animals given N-methylformamide and N-ethylformamide, but excretion profiles do not support the hypothesis that formamide is an active antitumour species formed from N-alkylformamides. No appreciable metabolism of N-methylformamide occurred under a variety of conditions with liver preparations in vitro. N-methylformamide, but not N-ethylformamide or formamide, reduced liver soluble non-protein thiols by 59.8% 1 h after administration of an effective antitumour dose.
